BACKGROUND: The combination of topoisomerase I and II chemotherapeutic agents has shown promising preclinical synergistic effects in the treatment of high-grade malignant brain tumors such as high-grade gliomas and choroid plexus carcinomas. To confirm the effectiveness of this treatment combination and determine its possible toxicity, we conducted a retrospective review of the charts of children who received the therapy. METHODS: Patients with relapsed malignant brain tumors who were given an individualized treatment of pegylated (PEG)-liposomal doxorubicin and topotecan were included in our study. PEG-liposomal doxorubicin was given intravenously at a dosage of 30-40 mg/m(2) over 4 h once every 4 weeks. Additionally, an intravenous formulation of topotecan was given orally twice daily and was increased on an individual basis from a starting dosage of 0.3 mg/m(2) per application to a total daily dosage of 0.6 mg/m(2). RESULTS: Eight patients were included. The main toxicity (NCI-CTC) after three cycles of the combination therapy was grade IV hematotoxicity (n = 3); grade III hematotoxicity (n = 2), grade III stomatitis (n = 1), grade III infection (n = 2), grade III diarrhea (n = 1); and grade II dermatitis (n = 1). In four patients, stable disease was achieved for 9, 23, more than 24, and more than 48 weeks, respectively. CONCLUSION: The schedule of PEG-liposomal doxorubicin with 30-40 mg/m(2) every 4 weeks in combination with oral topotecan resulted in tumor response, but the toxicity was high. An individualized increasing dose of PEG-liposomal doxorubicin 10-20 mg/m(2) every two weeks is now recommended.
BACKGROUND: The combination of topoisomerase I and II chemotherapeutic agents has shown promising preclinical synergistic effects in the treatment of high-grade malignant brain tumors such as high-grade gliomas and choroid plexus carcinomas. To confirm the effectiveness of this treatment combination and determine its possible toxicity, we conducted a retrospective review of the charts of children who received the therapy. METHODS:Patients with relapsed malignant brain tumors who were given an individualized treatment of pegylated (PEG)-liposomal doxorubicin and topotecan were included in our study. PEG-liposomal doxorubicin was given intravenously at a dosage of 30-40 mg/m(2) over 4 h once every 4 weeks. Additionally, an intravenous formulation of topotecan was given orally twice daily and was increased on an individual basis from a starting dosage of 0.3 mg/m(2) per application to a total daily dosage of 0.6 mg/m(2). RESULTS: Eight patients were included. The main toxicity (NCI-CTC) after three cycles of the combination therapy was grade IV hematotoxicity (n = 3); grade III hematotoxicity (n = 2), grade III stomatitis (n = 1), grade III infection (n = 2), grade III diarrhea (n = 1); and grade II dermatitis (n = 1). In four patients, stable disease was achieved for 9, 23, more than 24, and more than 48 weeks, respectively. CONCLUSION: The schedule of PEG-liposomal doxorubicin with 30-40 mg/m(2) every 4 weeks in combination with oral topotecan resulted in tumor response, but the toxicity was high. An individualized increasing dose of PEG-liposomal doxorubicin 10-20 mg/m(2) every two weeks is now recommended.
Authors: Neyssa M Marina; Debon Cochrane; Elaine Harney; Katie Zomorodi; Susan Blaney; Naomi Winick; Mark Bernstein; Michael P Link Journal: Clin Cancer Res Date: 2002-02 Impact factor: 12.531
Authors: M Valdivieso; M A Burgess; M S Ewer; B Mackay; S Wallace; R S Benjamin; M K Ali; G P Bodey; E J Freireich Journal: J Clin Oncol Date: 1984-03 Impact factor: 44.544
Authors: Sabine Wagner; Bernhard Erdlenbruch; Alfred Längler; Astrid Gnekow; Joachim Kühl; Michael Albani; Sigrid Völpel; Peter Bucsky; Angela Emser; Ove Peters; Johannes E A Wolff Journal: Cancer Date: 2004-04-15 Impact factor: 6.860
Authors: Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra Rümmele; Oliver Grauer; Annekatrin Bock; Christopher Dietmaier; Wolfgang Dietmaier; Jörg Dietrich; Christine Dudel; Franz Hübner; Tanya Jauch; Elisabeth Drechsel; Ingo Kleiter; Cäcile Wismeth; Anton Zellner; Alexander Brawanski; Andreas Steinbrecher; Jörg Marienhagen; Ulrich Bogdahn Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Kathryn M Camacho; Sunny Kumar; Stefano Menegatti; Douglas R Vogus; Aaron C Anselmo; Samir Mitragotri Journal: J Control Release Date: 2015-04-25 Impact factor: 9.776
Authors: Afrasim Moin; Syed Mohd Danish Rizvi; Talib Hussain; D V Gowda; Gehad M Subaiea; Mustafa M A Elsayed; Mukhtar Ansari; Abulrahman Sattam Alanazi; Hemant Yadav Journal: Life (Basel) Date: 2021-05-05